MoleSafe Names Kevin Sheridan CEO

Millburn, N.J. – MoleSafe, the world’s most advanced melanoma screening and surveillance program headquartered in Millburn, New Jersey, with its flagship location at New York University, announces the appointment of Kevin Sheridan as Chief Executive Officer.

A highly respected startup, growth and transition executive, Sheridan brings more than 37 years of business development experience primarily in healthcare, information technology, manufacturing and services industries. In his new role, Sheridan will focus on growing MoleSafe’s existing locations throughout the Tri-State area and expanding its footprint nationwide through standalone clinics, centers of excellence and consumer and corporate wellness programs.

“Kevin is a veteran executive with an entrepreneurial spirit who has successfully helped a number of companies grow and exceed business goals,” said Richard Bezozo, M.D., President of MoleSafe. “He’s passionate about growing and expanding MoleSafe’s presence throughout the United States to ensure that people at risk for melanoma have access to the most advanced screening and surveillance program available.”

Prior to accepting his new position as CEO of MoleSafe, he served as president of Sheridan Funding & Management, LLC, a company founded to invest in and provide management guidance to privately held early stage and rapidly growing business entities. Sheridan earned his Master of Business Administration in Finance from Fairleigh Dickenson University in Teaneck, New Jersey, and his Bachelor of Arts in Economics and Business from Lafayette College in Easton, Pennsylvania. Sheridan currently resides in Boonton, New Jersey.

For more information on MoleSafe and the benefits of its early detection screening and surveillance program, please visit www.molesafe.com. Like MoleSafe on Facebook at https://www.facebook.com/molesafe and follow its Twitter feed at https://twitter.com/MoleSafe_Inc.

About MoleSafe Inc.

MoleSafe is the world’s most advanced melanoma screening and surveillance program. Headquartered in Millburn, New Jersey, with its flagship location at New York University’s Langone Medical Center, MoleSafe’s comprehensive program incorporates a suite of advanced melanoma detection and diagnosis tools and technology, including total body photography, digital dermoscopy, and digital serial monitoring, to result in earlier detection of melanoma and reduce the unnecessary removal of benign lesions. Through its partnership with MoleMap, which offers the same screening services in Australia and New Zealand, more than 40 facilities have been established globally, and thousands of melanomas and other skin cancers have been diagnosed from more than 150,000 telemedicine consultations. For more information about MoleSafe, please visit www.molesafe.com.

###